SONN vs. HOTH, UPC, OGEN, GRAY, SNGX, GTBP, PULM, ATXI, KA, and YMTX
Should you be buying Sonnet BioTherapeutics stock or one of its competitors? The main competitors of Sonnet BioTherapeutics include Hoth Therapeutics (HOTH), Universe Pharmaceuticals (UPC), Oragenics (OGEN), Graybug Vision (GRAY), Soligenix (SNGX), GT Biopharma (GTBP), Pulmatrix (PULM), Avenue Therapeutics (ATXI), Kineta (KA), and Yumanity Therapeutics (YMTX). These companies are all part of the "pharmaceutical preparations" industry.
Sonnet BioTherapeutics (NASDAQ:SONN) and Hoth Therapeutics (NASDAQ:HOTH) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, risk, media sentiment, analyst recommendations, community ranking and institutional ownership.
9.5% of Sonnet BioTherapeutics shares are owned by institutional investors. Comparatively, 7.1% of Hoth Therapeutics shares are owned by institutional investors. 2.0% of Sonnet BioTherapeutics shares are owned by insiders. Comparatively, 3.3% of Hoth Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Sonnet BioTherapeutics currently has a consensus price target of $88.70, suggesting a potential upside of 4,618.09%. Hoth Therapeutics has a consensus price target of $7.67, suggesting a potential upside of 404.39%. Given Sonnet BioTherapeutics' higher possible upside, equities analysts clearly believe Sonnet BioTherapeutics is more favorable than Hoth Therapeutics.
Hoth Therapeutics has lower revenue, but higher earnings than Sonnet BioTherapeutics.
Hoth Therapeutics received 47 more outperform votes than Sonnet BioTherapeutics when rated by MarketBeat users. However, 80.95% of users gave Sonnet BioTherapeutics an outperform vote while only 62.75% of users gave Hoth Therapeutics an outperform vote.
In the previous week, Hoth Therapeutics had 2 more articles in the media than Sonnet BioTherapeutics. MarketBeat recorded 4 mentions for Hoth Therapeutics and 2 mentions for Sonnet BioTherapeutics. Hoth Therapeutics' average media sentiment score of 0.77 beat Sonnet BioTherapeutics' score of 0.44 indicating that Hoth Therapeutics is being referred to more favorably in the news media.
Hoth Therapeutics has a net margin of 0.00% compared to Sonnet BioTherapeutics' net margin of -11,187.19%. Hoth Therapeutics' return on equity of -102.79% beat Sonnet BioTherapeutics' return on equity.
Sonnet BioTherapeutics has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500. Comparatively, Hoth Therapeutics has a beta of 0.59, meaning that its stock price is 41% less volatile than the S&P 500.
Summary
Hoth Therapeutics beats Sonnet BioTherapeutics on 8 of the 13 factors compared between the two stocks.
Get Sonnet BioTherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SONN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SONN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Sonnet BioTherapeutics Competitors List
Related Companies and Tools